SINTILIMAB
Clinical trials for SINTILIMAB explained in plain language.
Never miss a new study
Get alerted when new SINTILIMAB trials appear
Sign up with your email to follow new studies for SINTILIMAB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New lung cancer combo shows promise in early trial
Disease control Recruiting nowThis study tests whether adding the drug sintilimab to standard chemotherapy and a personalized radiation plan can help control stage III non-small cell lung cancer. About 35 adults aged 18-75 who cannot have surgery will receive the combination. The main goal is to see how long …
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Promising new cocktail takes on deadly colorectal cancer
Disease control Recruiting nowThis study tests a combination of four drugs (sintilimab, ipilimumab, cetuximab, and dabrafenib) in people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. These cancers are hard to treat and don't respond well to sta…
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control Recruiting nowThis study tests whether giving two drugs (sintilimab and bevacizumab) before surgery can lower the chance of liver cancer coming back. It involves 37 adults with resectable liver cancer that is beyond standard transplant criteria. The goal is to see if this approach improves 1-y…
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New hope for brain cancer patients: drug cocktail trial opens
Disease control Recruiting nowThis study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) in 24 people with a type of brain lymphoma that has returned or is hard to treat. The goal is to see if the combo can shrink tumors and improve survival. Participants who respond may get a ste…
Matched conditions: SINTILIMAB
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated May 11, 2026 20:41 UTC